Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jesse Schulman who wrote (994)	2/10/2000 3:29:00 PM
From: yosi s	of 1386

Pharmos 1.Has cash for the next phase. 2. Has a new board member that has experience with phase 3 trial in Head trauma. 2a. that same board member was with Cambridge Sciences, their product failed, I do not think he would have joined Pharmos if he was not sure that HU 211 got a great chance. 3. As they have a board member joining. I suspect that they will get a partner to joint venture. Pharmos will participate in the cost yet the bulk of day to day operation will be done by the partner,as well as future marketing. Similar to BOL deal. Pharmos got the cash to carry its part. HU 211 results, though the study is done the tabulation etc takes time. My guess they will be ready at or prior to the Q year end 1999 announcement. Again this is my interpretation of events. Still waiting to see if Pharmos going to hire high level operational personal.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next